Sumitomo Dainippon Pharma Annual Report 2017

CSR ManagementThe United Nations has officially announced 17 Sustainable Development Goals to be accomplished by 2030, including “Goal 3: Good Health and Well-being,” as an applicable agenda for healthcare.Sumitomo Dainippon Pharma continues to make efforts for Access to Healthcare, through creating innovative new drugs with leading-edge Our approach to CSR-based managementContribution to the Achievement of Goal 3 of the SDGs: “Good Health and Well-being”We position practicing our Corporate Mission as one and the same with CSR-based management.Hajime KinutaExecutive OfficerSenior Director, Corporate Governance; Corporate Service CenterSumitomo Dainippon Pharma defines the practice of its Corporate Mission, “To broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide,” as CSR-based management. Sumitomo Dainippon Pharma sets forth its commitment to serve society in the Corporate Mission, and the aim of its operations, which are focused on its stakeholders, in the Management Mission. Our Declaration of Conduct specifies the content of our Mission in more concrete terms, and serves as our basic approach to promoting CSR. Through business activities conforming to our Declaration of Conduct, we are committed to providing products that are truly needed, while fulfilling our social responsibility as a corporation through wide-ranging initiatives that include the strengthening of our corporate governance system, thoroughly ensuring compliance, social contribution activities in and outside Japan, promotion of diversification, and active communication with diverse stakeholders.In promoting CSR-based management, we actively utilize the core subjects’ framework of ISO 26000 to assist in practice in addition to valuing dialogue with stakeholders. We work to enhance our approach appropriately to meet changes in the globalization of business and society with a focus on organizational governance, human rights, labor practices, the environment, fair operating practices, consumer issues, and community involvement and development.Moreover, we have been striving to participate in several partnership initiatives globally to undertake “SDG 3: Ensure healthy lives and promote well-being for all at all ages” of the Sustainable Development Goals (SDGs) of the United Nations.technologies in the focus therapeutic areas of Psychiatry & Neurology and Oncology, as well as new areas such as disease fields where no approved drugs exist and Regenerative Medicine & Cell Therapy, and providing support for countries and regions where the medical systems need to be improved.51Sumitomo Dainippon Pharma Co., Ltd. Annual Report 2017

元のページ  ../index.html#52